Trending Now

KYHOnline

Know Your Health, Stay Informed!!

Breaking News
Menu
Follow Us:
Search
Top News
Dr Ankit Deokar - Cornea Consultant and Chief Medical Officer - Sankara Eye Hospital - Indore
How Hazardous AQI Levels Are Threatening Eye Health: Here’s How to Keep Your Eyes Safe
Hamdard Laboratories Hosts AYUSH Convention 2025 in New Delhi
Hamdard Laboratories Hosts AYUSH Convention 2025 in New Delhi to Advance India’s Integrated Approach for Lifestyle Disease Management
Dr Aishwarya R - Consultant - Infectious Diseases - Aster Whitefield Hospital
How to live a healthy life with HIV: Doctor says don’t ignore nutrition and exercise, give up alcohol and smoking
Dr Aishwarya R - Consultant - Infectious Diseases - Aster Whitefield Hospital
World AIDS Day 2025: Signs And Symptoms Of HIV You Should Not Ignore
Apollo Hospitals Enterprise Limited Logo
Apollo Hospitals Marks 27 Years of Successful Pediatric Liver Transplantation in India Organizes a workshop, training program and CME in pediatric gastroenterology and hepatology
Dr Anubbha - BHMS - Classical Homeopathy Specialist - Dr Anubbhas Homeopathy
Understanding the rise of Scrub typhus – and how to stay protected
Wellbeing Nutrition extends its portfolio into kids nutrition with the launch of Kids Superfuel
Wellbeing Nutrition extends its portfolio into kids nutrition with the launch of ‘Kids Superfuel’
Medline Academics successfully hosted its Convocation Ceremony 2025
Medline Academics & Dr. Kamini Rao Hospitals Successfully Conclude the Grand Convocation Ceremony 2025
Dr Kushal Banerjee - Dr Kalyan Banerjees Clinic
Homeopathy: A Potential Long-term Solution for Seasonal Allergies in Winter

Tag: subcutaneous PD-L1 inhibitor

Pharma
Know Your Health Team

Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer

Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The Company has received approval from the Drugs Controller General of India (DCGI) […]

Back To Top